ADAP Overview

Delisting Announcement: Adaptimmune Therapeutics plans to voluntarily delist its American Depositary Shares (ADS) from Nasdaq, with a filing expected on or about October 28, 2025, to facilitate cost reductions and maximize value.

Future Trading Plans: Following the delisting, the company anticipates its ADSs will be traded on the OTC Pink Limited Market, with trading on Nasdaq expected to be suspended around October 27, 2025.

Stock Performance: Adaptimmune Therapeutics PLC (ADAP) has seen a significant stock surge of 52% followed by an 11% increase in pre-market trading, despite a low “Sell (E+)” rating from Weiss Ratings, indicating speculative momentum rather than strong fundamentals.

Financial Concerns: The stock remains down over 60% this year and has fallen more than 75% in the past 12 months, with analysts expressing concerns over the company's financial health, including declining revenues and persistent losses, leading to a cautious outlook for investors.

Stock Performance: AlphaVest Acquisition (ATMV) shares surged by 69% in premarket trading on a recent Friday.

Market Activity: The significant increase in share price indicates strong investor interest and market activity surrounding the company.

FedEx Financial Results: FedEx Corporation's shares rose 4.8% in pre-market trading after reporting better-than-expected Q1 fiscal 2026 results, with projected revenue growth of 4% to 6% and plans for $1 billion in permanent cost reductions.

Pre-Market Stock Movements: AGM Group Holdings saw a significant 111.6% increase after a sale announcement, while other notable gainers included AlphaVest Acquisition Corp (+71.4%) and 22nd Century Group (+45.5%). Conversely, Reviva Pharmaceuticals experienced a sharp decline of 28.8% following a public offering announcement.

Adaptimmune Therapeutics Surge: Adaptimmune Therapeutics plc (ADAP) saw a dramatic after-hours increase of 30% following a nearly 98% gain during regular trading, driven by renewed investor interest despite no specific news. The company reported a net loss of $30.3 million for Q2 2025 but has made strategic moves, including selling cell therapies for $55 million.

Butterfly Network Recognition: Butterfly Network Inc. (BFLY) rose 10.58% in after-hours trading after being named one of TIME's Top HealthTech Companies for 2025, alongside a recent appointment of a new CTO. The company’s technology has been validated by a JAMA study showing significant reductions in hospital stays and costs.

Aquestive Therapeutics Positive Outlook: Aquestive Therapeutics Inc. (AQST) continued its upward trend with a 7.69% increase in after-hours trading, bolstered by FDA confirmation that no advisory committee meeting is needed for its NDA for Anaphylm, streamlining the approval process. The company also secured $75 million in strategic funding.

Insider Confidence at ALX Oncology: ALX Oncology Holdings Inc. (ALXO) gained 9.17% in after-hours trading, attributed to insider buying by CEO Jason Lettmann, signaling confidence in the company. ALXO's lead candidate, Evorpacept, is currently in multiple clinical trials, maintaining investor interest despite no new data releases.

Surge in Healthcare Stocks: On September 12, several healthcare and biotech stocks, including Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma, saw significant after-hours trading gains, driven by strategic announcements and clinical milestones, despite some movements occurring without direct news.

Penumbra's Stock Performance: Penumbra Inc. experienced a rebound in after-hours trading, rising 6.28% to $289.86, following a decline during regular hours. The company raised its full-year revenue guidance and appointed a new president, indicating confidence in its growth trajectory.

Check-Cap's Merger Announcement: Check-Cap Ltd. saw its stock soar by 191.22% after announcing a merger with MBody AI, which aims to enhance its colorectal cancer screening technology with AI capabilities, potentially transforming its strategic direction.

NewAmsterdam Pharma's Regulatory Progress: NewAmsterdam Pharma's shares rose 8.23% after-hours, driven by positive investor sentiment regarding its lead candidate obicetrapib and recent regulatory milestones, including accepted Marketing Authorization Applications by the EMA and promising trial data related to Alzheimer's disease biomarkers.